tradingkey.logo

Viking Therapeutics Announces Positive Top-Line Results From Phase 2 Venture-Oral Dosing Trial Of Vk2735 Tablet Formulation In Patients With Obesity

ReutersAug 19, 2025 11:39 AM

Viking Therapeutics Inc VKTX.O:

  • VIKING THERAPEUTICS ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 2 VENTURE-ORAL DOSING TRIAL OF VK2735 TABLET FORMULATION IN PATIENTS WITH OBESITY

  • VIKING THERAPEUTICS INC - STUDY ACHIEVES ENDPOINTS WITH SIGNIFICANT WEIGHT REDUCTION USING VK2735

  • VIKING THERAPEUTICS INC - UP TO 12.2% MEAN WEIGHT LOSS WITH VK2735 AFTER 13 WEEKS

  • VIKING THERAPEUTICS INC - VK2735 SHOWN TO BE SAFE AND WELL-TOLERATED IN 13-WEEK STUDY

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Related Articles

Tradingkey
KeyAI